Compositions comprising azelastine and methods of use thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/56
A61K-031/57
A61K-031/573
A61K-031/58
A61K-031/575
A61P-011/02
A61P-027/14
A61P-029/00
A61P-037/08
A61K-009/00
A61K-009/70
A61K-031/55
A61K-045/06
출원번호
US-0284836
(2011-10-28)
등록번호
US-10064817
(2018-09-04)
발명자
/ 주소
Dang, Phuong Grace
Lawrence, Brian D.
Balwani, Gul
D'Addio, Alexander D.
출원인 / 주소
Meda Pharmaceuticals Inc.
인용정보
피인용 횟수 :
0인용 특허 :
127
초록▼
The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically
The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders.
대표청구항▼
1. An intranasal pharmaceutical product, comprising a liquid pharmaceutical composition comprising: (i) from about 0.05% to about 0.5% (w/v) azelastine hydrochloride, (ii) from about 0.01% to about 1.0% (w/v) fluticasone propionate, and (iii) from about 0.1% to about 0.5% (w/v) sucralose, wherein th
1. An intranasal pharmaceutical product, comprising a liquid pharmaceutical composition comprising: (i) from about 0.05% to about 0.5% (w/v) azelastine hydrochloride, (ii) from about 0.01% to about 1.0% (w/v) fluticasone propionate, and (iii) from about 0.1% to about 0.5% (w/v) sucralose, wherein the composition in the intranasal pharmaceutical product is formulated for intranasal administration in a human. 2. The intranasal pharmaceutical product of claim 1, further comprising one or more additional active agents selected from the group consisting of one or more decongestants, one or more antihistamines, one or more non-steroidal anti-inflammatory agents and one or more leukotriene antagonists. 3. The intranasal pharmaceutical product of claim 1, wherein said azelastine hydrochloride is present in said composition at a concentration of from about 0.125% to about 0.15% (w/v). 4. The intranasal pharmaceutical product of claim 1, wherein said azelastine hydrochloride is present in said composition at a concentration of from about 0.05% to about 0.15% (w/v). 5. The intranasal pharmaceutical product of claim 1, wherein said liquid pharmaceutical composition is contained within an intranasal delivery system. 6. The intranasal pharmaceutical product of claim 5, wherein said intranasal delivery system comprises a bottle and a pump. 7. The intranasal pharmaceutical product of claim 6, wherein pump is a metered multi-dose pump. 8. The intranasal pharmaceutical product of claim 1, wherein said liquid pharmaceutical composition is in the form of a nasal spray. 9. The intranasal pharmaceutical product of claim 1, wherein said liquid pharmaceutical composition is in the form of nasal drops. 10. The intranasal pharmaceutical product of claim 1, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.07 to about 0.15 ml per spray. 11. The intranasal pharmaceutical product of claim 10, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.14 ml per spray. 12. The intranasal pharmaceutical product of claim 1, wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.2% (w/v). 13. The intranasal pharmaceutical product of claim 1, wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.15% (w/v). 14. The intranasal pharmaceutical product of claim 1, wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.15% (w/v). 15. The intranasal pharmaceutical product of claim 1, wherein said azelastine hydrochloride in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.15% (w/v). 16. The intranasal pharmaceutical product of claim 1, wherein said liquid pharmaceutical composition further comprises sorbitol. 17. The intranasal pharmaceutical product of claim 16, wherein said sorbitol in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 10% (w/v) sorbitol 70%. 18. The intranasal pharmaceutical product of claim 16, wherein said sorbitol in said liquid pharmaceutical composition is present at a concentration of about 6.4% (w/v) sorbitol 70%. 19. A method of treating allergic rhinitis, non-allergic vasomotor rhinitis or allergic conjunctivitis in a human suffering from or predisposed thereto, comprising intranasally administering to said human an effective amount of the intranasal pharmaceutical product of claim 1. 20. The method of claim 19, wherein said liquid pharmaceutical composition is contained within an intranasal delivery system. 21. The method of claim 20, wherein said liquid pharmaceutical composition is in the form of a nasal spray. 22. The method of claim 19, wherein said liquid pharmaceutical composition further comprises sorbitol. 23. The method of claim 19, wherein said liquid pharmaceutical composition is contained within an intranasal delivery system. 24. The method of claim 23, wherein said intranasal delivery system comprises a bottle and a pump. 25. The method of claim 24, wherein said pump is a metered multi-dose pump. 26. The method of claim 19, wherein said liquid pharmaceutical composition is in the form of nasal drops. 27. The method of claim 19, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.07 to about 0.15 ml per spray. 28. The method of claim 27, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.14 ml per spray. 29. The method of claim 19, wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.2% (w/v). 30. The method of claim 19, wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.15% (w/v). 31. The method of claim 19, wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.15% (w/v). 32. The method of claim 19, wherein said azelastine hydrochloride in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.15% (w/v). 33. The method of claim 19, wherein said liquid pharmaceutical composition further comprises sorbitol. 34. The method of claim 33, wherein said sorbitol in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 10% (w/v) sorbitol 70%. 35. The method of claim 33, wherein said sorbitol in said liquid pharmaceutical composition is present at a concentration of about 6.4% (w/v) sorbitol 70%.
Findlay John W. A. (Rte. 2 ; Box 514 Chapel Hill NC) Coker Geoffrey G. (No. 80 Pickhurst Park Bromley ; Kent GB2), 3-{6-[3-Pyrrolidino-1-(4-tolyl)prop-1-enyl]-2-pyridyl}acrylic acid and pharmaceutically acceptable salts thereof.
Cupps Thomas Lee ; Maurer Peter J. ; Ares Jeffrey J. ; Henry Raymond T. ; Sheldon Russell James ; Mieling Glen E. ; Bogdan Sophie E., 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists.
Kutscher Bernhard (Maintal DEX) Niebch Georg (Rodenbach DEX) Fleischhauer Ilona (Offenbach DEX) Engel Jrgen (Alzenau DEX) Achterrath-Tuckermann Ute (Maintal DEX) Szelenyi Stefan (Schwaig DEX), Aminocarboxylic acid derivatives having antiallergic/antiasthmatic effect and a process for their preparation.
Phillipps Gordon H. (Wembley GB2) Bain Brian M. (Chalfont St. Peter GB2) Steeples Ian P. (Ruislip Manor GB2) Williamson Christopher (Cobham GB2), Androstane carbothioates.
Stokbroekx, Raymond Antoine; Ceusters, Marc Andre; Van der Aa, Marcel Jozef Maria; Luyckx, Marcel Gerebernus Maria; Willems, Marc; Tuman, Robert W., Angiogenesis inhibiting thiadiazolyl pyridazine derivatives.
Bosmans, Jean-Paul Rene Marie Andre; De Cleyn, Michel Anna Jozef; Surkyn, Michel, Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives.
Sunshine Abraham (New York NY) Laska Eugene M. (Larchmont NY) Siegel Carole E. (Mamaroneck NY), Cough/cold mixtures comprising non-sedating antihistamine drugs.
Sunshine Abraham (New York NY) Laska Eugene M. (Larchmont NY) Siegel Carole E. (Mamaroneck NY), Cough/cold mixtures comprising non-sedating antihistamine drugs.
Jaeger, Joachim; Cirillo, Pasquale; Eicher, Joachim; Geser, Johannes; Freund, Bernhard; Zierenberg, Bernd, Device for producing high pressure in a fluid in miniature.
Jaeger, Joachim; Cirillo, Pasquale; Eicher, Joachim; Geser, Johannes; Freund, Bernhard; Zierenberg, Bernd, Device for producing high pressure in a fluid in miniature.
Joachim Jaeger DE; Pasquale Cirillo DE; Joachim Eicher DE; Johannes Geser DE; Bernhard Freund DE; Bernd Zierenberg DE, Device for producing high pressure in a fluid in miniature.
Joachim Jaeger DE; Pasquale Cirillo DE; Joachim Eicher DE; Johannes Geser DE; Bernhard Freund DE; Bernd Zierenberg DE, Device for producing high pressure in a fluid in miniature.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Bosmans, Jean-Paul René Marie André; De Cleyn, Michel Anna Jozef; Surkyn, Michel, Gastrokinetic monocyclic benzamides of 3-or 4-substituted 4-(aminoethyl)-piperidine derivatives.
Weinstein Robert E. ; Weinstein Alan M., Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the tre.
Weinstein Robert E. ; Weinstein Allan M., Method and device for organizing and coordinating the combined use of topical aerosols for the treatment of respiratory.
Robert E. Weinstein ; Allan M. Weinstein, Method and device for organizing and coordinating the combined use of topical agents for the treatment of respiratory disorders.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Hettche Helmut (Dietzenbach DEX) Muckenschnabel Reinhard (Frankfurt DEX) Scheffler Gerhard (Bruchkbel DEX) Fleischhauer Ilona (Offenbach DEX) Morick Wolfgang (Frankfurt DEX), Method of treating inflammatory disorders and psoriasis with salts of azelastine.
Engel Jrgen (Alzenau DEX) Scheffler Gerhard (Hanau DEX), N-benzyl, phenethyl, methoxyethyl or allyl substituted benzylphthalazinones having antiallergic and antihistamine action.
Wenig Jeffrey (Dix Hills NY), Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms co.
Shue Ho-Jane ; Shih Neng-Yang ; Blythin David J. ; Chen Xiao ; Tom Wing C. ; Piwinski John J. ; McCormick Kevin D., Piperazino derivatives as neurokinn antagonists.
Cortese Richard (San Jose CA) Barclay Brian (Menlo Park CA) Theeuwes Felix (Los Altos CA), Simultaneous delivery of two drugs from unit delivery device.
Hofmeister, Armin; Heinelt, Uwe; Lang, Hans-Jochen; Bleich, Markus; Wirth, Klaus; Gekle, Michael, Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them.
Reichard Gregory A. (Morris Plains NJ) Aslanian Robert G. (Rockaway NJ) Alaimo Cheryl A. (Somerset NJ) Kirkup Michael P. (Lawrenceville NJ) Lupo ; Jr. Andrew (Emerson NJ) Mangiaracina Pietro (Monsey , Substituted oximes, hydrazones and olefins as neurokinin antagonists.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.